RAD-150

RAD-150, also sold under the name TLB-150 Benzoate, is a research chemical marketed as a benzoate ester of RAD-140 (Testolone), one of the better-known selective androgen receptor modulators (SARMs) ^[1]. In vendor descriptions the addition of a benzoate ester group is presented as analogous to the esterification of testosterone, a modification intended to slow release and extend the compound's duration of action; it is important to note that this rationale comes from marketing and chemical analogy rather than from published pharmacokinetic studies of RAD-150 itself ^[1].

SARMs are a class of compounds that bind the androgen receptor, the same receptor activated by testosterone, and were designed to promote anabolic effects in muscle and bone while limiting androgenic effects elsewhere; despite substantial pharmaceutical research into indications such as muscle wasting and cachexia, no SARM has received full clinical approval ^[1]. RAD-150 is a newer entrant to this market and, unlike its parent RAD-140, has essentially no dedicated scientific literature: it has not been characterized in published human or animal studies, and any account of its effects is extrapolated from RAD-140 and the SARM class rather than from direct evidence ^[1].

RAD-150 is not approved by the United States Food and Drug Administration or any comparable regulator, and as a SARM-class agent it falls under the World Anti-Doping Agency Prohibited List, making it banned in competitive sport ^[1]. It is sold as a research chemical, typically as a liquid solution or capsules, in a market where analytical studies have repeatedly found SARM products to be mislabeled or to contain undisclosed ingredients ^[7]. Given that the closely related RAD-140 has been the subject of medical case reports describing serious adverse events, the absence of safety data specific to RAD-150 is a significant concern rather than a reassurance ^[2][3][4].

RAD-150 (TLB-150) is an unapproved research SARM, a benzoate ester of RAD-140, with no data supporting human use and no status as a licensed medicine. Like other androgen receptor agonists it is expected to suppress the hypothalamic-pituitary-testicular axis and lower natural testosterone, reduce HDL cholesterol, and strain the liver, and drug-induced liver injury has been reported with RAD-140. Its long-term and cardiovascular safety in humans are unknown.

RAD-150, marketed as TLB-150 Benzoate, is a research chemical presented as a benzoate ester of the selective androgen receptor modulator RAD-140 (Testolone). RAD-140 itself was developed by the biopharmaceutical company Radius Health and first described in the scientific literature around 2011 as a nonsteroidal androgen receptor agonist for muscle wasting and other indications. RAD-150 emerged later within the supplement and research-chemical trade, promoted on the analogy of testosterone esters, which release their active molecule gradually, as a longer-acting version of RAD-140.

Crucially, this claim has never been tested: RAD-150 has no published pharmacological or clinical studies of its own, and everything inferred about it is extrapolated from its parent compound and the broader SARM class. It has never been an approved drug, was not created through any formal clinical development program, and is banned in sport by the World Anti-Doping Agency. As such it has essentially no documented scientific history beyond that of RAD-140.

RAD-150 is marketed to bodybuilders as an improved, longer-acting cousin of the popular RAD-140, and it carries some of that reputation for driving muscle and strength gains by association. It is important to be candid that this reputation is almost entirely borrowed: because no published study has ever characterized RAD-150's potency, pharmacokinetics, or safety in humans or animals, its supposed advantages remain unverified marketing claims.

The evidence that does exist concerns its parent, RAD-140, and it is cautionary; RAD-140 has been linked in case reports to serious liver injury and cardiovascular harm in young users, and a rodent study found it worsened frailty and survival. Given that RAD-150 is chemically close to RAD-140 but even less studied, and that SARM products are frequently mislabeled, the honest assessment is that its benefits are speculative while the documented risks of its parent compound should be treated as the most relevant guide.